More Articles

Perrigo receives tentative FDA approval for generic Prandin Generics/News | Posted 09/08/2013

US-based drugmaker Perrigo Company (Perrigo) announced on 19 July 2013 that it had received tentative approval from FDA for its abbreviated new drug application (ANDA) for repaglinide tablets.

How to avoid drug shortages Reports | Posted 09/08/2013

Despite FDA having made progress in recent years to combat drug shortages, the issue is still a major problem for the agency. This very fact led to the agency requesting public comment on the subje...

Aspen makes deals with Merck and GSK Pharma News | Posted 09/08/2013

Generics manufacturer Aspen Pharmacare Holdings (Aspen) is expanding its brand-name business, first signing a deal with Pharma giant Merck, and then offering to buy two brand-name heart medications...

Indian generics companies top ANDA approvals Generics/General | Posted 09/08/2013

Indian generics companies are beating many other countries when it comes to gaining US FDA approval for their generic drugs.

EMA reviewing biosimilar insulin application Biosimilars/News | Posted 02/08/2013

According to EMA’s list of applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use released on 4 July 2013 the agency is now reviewing a new appl...

Biosimilar G-CSF prescribed more than originator Biosimilars/News | Posted 02/08/2013

Sandoz, the generic drug division of Swiss drug giant Novartis, announced on 22 July 2013 that its biosimilar granulocyte colony-stimulating factor (G-CSF) Zarzio (filgrastim) has overtaken the ori...

Use of brand-name drugs increasing healthcare costs in US Generics/Research | Posted 02/08/2013

Patients with diabetes who are covered by the US healthcare insurance Medicare are two to three times more likely to use expensive brand-name drugs compared to patients treated within the Veterans...

CFR pharma expands global ambitions with Adcock bid Pharma News | Posted 02/08/2013

Chile-based CFR Pharmaceuticals (CFR) has plans to become a global drugmaker. In its latest efforts it has made a US$1.3 billion cash-and-share offer for South Africa’s second-largest generics drug...